Cabozantinib as a second-line treatment option in hepatocellular carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387.
   PubMed Web of Science ®Google Scholar
• Ghouri Y, Mian I, Rowe J. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
   PubMedGoogle Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2018;29:iv238–iv255.
   PubMed Web of Science ®Google Scholar
• Mak L-Y, Cruz-Ramón V, Chinchilla-López P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2018;38:262–279.
   PubMedGoogle Scholar
• Desai JR, Ochoa S, Prins PA, et al. Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol. 2017;8:243–255.
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563–573.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. .
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Lin D-Y, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–4075.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Qin S, Park J-W, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–3524.
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang W-T, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–179.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans TRJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559–566.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Niedzwieski D, Knox JJ, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol. 2016;34:4003.
   Web of Science ®Google Scholar
• Raoul J-L, Kudo M, Finn RS, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. Cancer Treat Rev. 2018;68:16–24.
   PubMed Web of Science ®Google Scholar
• EMA. EMA Recommends Extension of Indications for Lenvatinib.
   Google Scholar
• USA FDA. FDA approves lenvatinib for unresectable hepatocellular carcinoma | FDA.
   Google Scholar
• Casadei Gardini A, Puzzoni M, Montagnani F, et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. Onco Targets Ther. 2019;12:2981–2988.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. .
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafe. J Clin Oncol. 2018;36:4003.
   Web of Science ®Google Scholar
• Merck Co. Merck Provides Update on KEYNOTE-240 a P 3 S of K, in Previously Treated Patients with Advanced Hepatocellular Carcinoma. Merck & Co., Inc. - Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma.
   Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.
   PubMed Web of Science ®Google Scholar
• Li D, Sedano S, Allen R, et al. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers (Basel). 2019;11:841.
   PubMed Web of Science ®Google Scholar
• Exelixis Inc. CABOMETYX® (cabozantinib) tablets for oral use: US prescribing information. 2019.
   Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a Novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298–2308.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20:2959–2970.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Cabozantinib: a review in advanced hepatocellular carcinoma. Target Oncol. 2019;14:107–113.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Benrimoh N, Xie Y, et al. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs. 2016;27:669–678.
   PubMed Web of Science ®Google Scholar
• Ipsen Pharma. Cabometyx film-coated tablets: EU summary of product characteristics. 2019.
   Google Scholar
• Nguyen L, Holland J, Ramies D, et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016;56:1130–1140.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Chapel S, Tran BD, et al. Updated population pharmacokinetic model of cabozantinib integrating various cancer types including hepatocellular carcinoma. J Clin Pharmacol. 2019 Nov;59(11):1551–1561. DOI:10.1002/jcph.1467.
   Web of Science ®Google Scholar
• Schöffski P, Gordon M, Smith DC, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017;86:296–304.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63.
   PubMed Web of Science ®Google Scholar
• Marino D, Zichi C, Audisio M, et al. Second-line treatment options in hepatocellular carcinoma. Drugs Context. 2019;8:1–13.
   Google Scholar
• Yau T, Merle P, Rimassa L, et al. Assessment of tumor response, alpha-fetoprotein (AFP) ase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatoresponse, and time to progression (TTP) in the phcellular carcinoma (HCC). Ann Oncol. 2018 Nov 1;29(suppl_9):ix46–ix66. DOI:10.1093/annonc/mdy432.
   Web of Science ®Google Scholar
• Blanc JF, Meyer T, Cheng A-L, et al. 703PAssessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2018;29. DOI:10.1093/annonc/mdy282.086
   PubMed Web of Science ®Google Scholar
• Yau T, Cheng A-L, Meyer T, et al. 704POutcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol. 2018;29. DOI:10.1093/annonc/mdx807
   PubMed Web of Science ®Google Scholar
• Rimassa L, Cicin I, Blanc J-F, et al. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2018;36:4090.
   Web of Science ®Google Scholar
• Kwilas AR, Ardiani A, Donahue RN, et al. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12:294. .
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu X-D, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687–2697.
   PubMed Web of Science ®Google Scholar
• Shojaei F, Lee JH, Simmons BH, et al. HGF/c-met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70:10090–10100.
   PubMed Web of Science ®Google Scholar
• Kudo M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma. Liver Cancer. 2018;7:123–133.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang K, Yan Z, et al. Axl expression stratifies patients with poor prognosis after hepatectomy for hepatocellular carcinoma. PLoS One. 2016;11:e0154767. Coleman WB, editor
   PubMed Web of Science ®Google Scholar
• Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology. 1997;25:862–866.
   PubMed Web of Science ®Google Scholar
• Fung AS, Tam VC, Meyers DE, et al. Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S). J Clin Oncol. 2019;37:422.
   Web of Science ®Google Scholar
• Brizzi MP, Pignataro D, Tampellini M, et al. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?. Expert Rev Anticancer Ther. 2016;16:1053–1062.
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Seufferlein T Regorafenib. Recent Results Cancer Res. [Internet]. Springer New York LLC; 2018 [cited 2020 Apr 8]. p. 45–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30069758
   Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37:4004.
   Web of Science ®Google Scholar
• Roskell N, Gregory J, Wisniewski T, et al. Indirect treatment comparisons of nivolumab versus regorafenib, cabozantinib and best supportive care after treatment with sorafenib for hepatocellular carcinoma. BresMed. 2018 Oct 1;21(suppl_3):S17–S18.
   Google Scholar
• Nasr; ZBAER. Second-line treatments of advanced hepatocellular carcinoma: systematic review and network meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2019;53:251–261.
   PubMed Web of Science ®Google Scholar